Based on these results, MIP-1α and IL-6 were then selected as potential candidate targets of sympathetic signaling in breast cancer and proceeded to validate the array by quantifying the expression of these cytokines by ELISA. The gene discussed is CCL3; the disease is breast carcinoma.